Recent years have shown a tremendous increase and diversification in antibody-based
therapeutics with advances in production techniques and formats. The plethora of currently …

Diseases are multifactorial, with redundancies and synergies between various pathways.
However, most of the antibody-based therapeutics on the market interact with only one …

The toolbox of modern antibody engineering allows the design of versatile novel
functionalities exceeding nature's repertoire. Many bispecific antibodies comprise …

Bispecific antibodies can uniquely influence cellular responses, but selecting target
combinations for optimal functional activity remains challenging. Here we describe a high …

Bispecific antibodies, engineered to recognize two targets simultaneously, demonstrate
exceptional clinical potential for the therapeutic intervention of complex diseases. However …

During the past two decades we have seen a phenomenal evolution of bispecific antibodies
for therapeutic applications. The 'zoo'of bispecific antibodies is populated by many different …

Background: Progress in molecular biology for the production of bispecific antibodies
(BiAbs) and the expanding knowledge on receptors on malignant and normal target cells …

Bispecific antibodies (bsAbs) target two different epitopes. These are an up-and-coming
class of biologics, with two such therapeutics (emicizumab and blinatumomab) FDA …

ABSTRACT Introduction: Bispecific antibodies (BsAb) are emerging as a novel approach for
dual targeting strategies. Two bispecific antibodies are approved for therapy and> 30 are in …

The ability of monoclonal antibodies to specifically bind a target antigen and neutralize or
stimulate its activity is the basis for the rapid growth and development of the therapeutic …